This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, D. Articles by Mohler, J. L. Search for Related Content PubMed PubMed Citation Articles by Kim, D. Articles by Mohler, J. L.

(American Journal of Pathology. 2002;160:219-226.)
© 2002 American Society for Investigative Pathology

Regular Articles

Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft

Desok Kim^*, Christopher W. Gregory, Frank S. French^*, Gary J. Smith^* and James L. Mohler^*

From the Lineberger Comprehensive Cancer Center,^*
the Department of Pediatrics,
the Laboratories for Reproductive Biology,
Department of Surgery, Division of Urology, and the Department of Pathology and Laboratory Medicine,
University of North Carolina, Chapel Hill, North Carolina

Androgen receptor expression was analyzed in the CWR22 human prostate cancer xenograft model to better understand its role in prostate cancer recurrence after castration. In androgen-dependent tumors, 98.5% of tumor cell nuclei expressed androgen receptor with a mean optical density of 0.26 ± 0.01. On day 2 after castration androgen deprivation decreased immunostained cells to 2% that stained weakly (mean optical density, 0.16 ± 0.08). Cellular proliferation measured using Ki-67 revealed <1% immunostained cells on day 6. Androgen receptor immunostained cells increased to 63% on day 6 and 84% on day 32 although immunostaining remained weak. Cellular proliferation was undetectable beyond day 6 after castration until multiple foci of 5 to 20 proliferating cells became apparent on day 120. These foci expressed increased levels of prostate-specific antigen, an androgen receptor-regulated gene product. In tumors recurrent 150 days after castration androgen receptor-immunostaining intensity was similar to CWR22 tumors from intact mice although the percentage of cells immunostained was more variable. The appearance of proliferating tumor cells that expressed androgen receptor and prostate-specific antigen 120 days after castration suggests that these cells represent the origin of recurrent tumors.

This article has been cited by other articles:

				H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587. [Abstract] [Full Text] [PDF]

				S Darby, J Stockley, M M Khan, C N Robson, H Y Leung, and V J Gnanapragasam Expression of GnRH type II is regulated by the androgen receptor in prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 613 - 624. [Abstract] [Full Text] [PDF]

				D. Feltquate, L. Nordquist, C. Eicher, M. Morris, O. Smaletz, S. Slovin, T. Curley, A. Wilton, M. Fleisher, G. Heller, et al. Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7414 - 7421. [Abstract] [Full Text] [PDF]

				L. Jia, H. C. Shen, M. Wantroba, O. Khalid, G. Liang, Q. Wang, E. Gentzschein, J. K. Pinski, F. Z. Stanczyk, P. A. Jones, et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol. Cell. Biol., October 1, 2006; 26(19): 7331 - 7341. [Abstract] [Full Text] [PDF]

				Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]

				H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130. [Abstract] [Full Text] [PDF]

				J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French The Androgen Axis in Recurrent Prostate Cancer Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448. [Abstract] [Full Text] [PDF]

				J. P. Dyke, K. L. Zakian, W. M. Spees, C. Matei, Y. Chen, X. Mao, D. C. Shungu, and J. A. Koutcher Metabolic Response of the CWR22 Prostate Tumor Xenograft after 20 Gy of Radiation Studied by 1H Spectroscopic Imaging Clin. Cancer Res., October 1, 2003; 9(12): 4529 - 4536. [Abstract] [Full Text] [PDF]

				T. Hara, K. Nakamura, H. Araki, M. Kusaka, and M. Yamaoka Enhanced Androgen Receptor Signaling Correlates with the Androgen-refractory Growth in a Newly Established MDA PCa 2b-hr Human Prostate Cancer Cell Subline Cancer Res., September 1, 2003; 63(17): 5622 - 5628. [Abstract] [Full Text] [PDF]